Information Provided By: 
Fly News Breaks for April 3, 2019
VIVO
Apr 3, 2019 | 08:36 EDT
Baird analyst Catherine Ramsey Schulte lowered her price target on Meridian Bioscience to $14 from $17 and maintained a Neutral rating after the company reported preliminary Q2 revenue well below the Street, with the miss mostly driven by Diagnostics, with particular weakness in molecular and respiratory issues. The analyst says she remains on the sidelines, as she believes ongoing headwinds are likely to persist near-term and management's new strategy will likely take time to drive better results.
News For VIVO From the Last 2 Days
There are no results for your query VIVO
